



For Immediate Release
Press Contact:
Susana Suarez
617-633-8927

Aria Diagnostic Laboratories Partnering with Clinics in New Hot Zones Provides Testing Materials to Clinics in Arizona, Texas, Florida and NC

INDIANAPOLIS, July 3, 2020---Aria Diagnostic Laboratories announced today it is partnering with clinics across the hard-hit states of Texas, Florida and Arizona to help with the dramatic increase in demand for tests. For the past few weeks, Aria and its sister company Apex Medical, has been working with local clinics in Houston, Phoenix and Naples, to provide COVID-19 collection kits. These collection kits are being provided to state agencies, testing labs, and other entities that are actively collecting specimens from individuals.

“We are working with clinics and companies around the US, particularly in these hard-hit hot zones, to provide the testing supplies they need to help get as many people tested as they can.” said Zak Khan, Co-Founder of Aria Diagnostic Laboratories. “Our guiding principle has always been that to get ahead of this pandemic, we need to test everyone.”

Aria’s goal is to get as many testing supplies as possible out to those that need it the most in order to help provide the peace of mind that people, businesses and governments need to reopen the economy safely. “The country is only utilizing 10% of its testing capacity,” said Vipin Adhlakha, President and co-founder of Aria. “We haven’t maxed out our production capacity and are very disappointed when we hear people are still having problems getting tested. We have enough supplies to produce 5 million kits – to date we have produced and shipped just under 2 million.”

Collection kits have been sent directly to a variety of organizations, primarily testing labs, clinics, large employee organizations, and government agencies in North Carolina, Texas, Florida, Arizona, Ohio, Illinois, Michigan, South Carolina, Louisiana, and many others.

“The demand for tests is tremendous, especially with the current resurgence around the country. With our current testing supplies, and our new promising study on saliva testing, plus our two new locations in Indiana, we believe that Aria can provide the most affordable, accessible and accurate tests to individuals, cities, states and companies.”

The demand for the FDA approved IgG and PCR based COVID-19 tests has grown so much that Aria has recently announced it is opening two additional test sites in Zionsville and Fishers, IN. Users can request a test online and set up a date and time for them to visit the drive-through testing sites at any of their locations. The medical staff will perform the PCR based test nasal swab collection while the patient remains in the car. Blood draws for the antibody test are performed in a tent at the drive thru site. Results will be sent via email within 72 hours.



After successfully providing thousands of COVID-19 test kits to area municipalities and New York City, as well as numerous companies and first responders, Aria Diagnostics has continued to seek out solutions to help get Hoosiers and people around the country get back to resuming normal activity with the peace of mind that they are not carrying or contagious of the virus that causes Covid-19. "It's not just about getting back to work," Khan said. "It's about getting back to Life."

About ARIA Diagnostics

ARIA Diagnostics is a high-complexity, CLIA-certified, CAP-accredited clinical diagnostic reference laboratory located in Indianapolis with over a quarter million patient specimens' experience delivering timely, accurate, clinically actionable information through our nationwide medication monitoring and drug testing services. Drug testing is used by substance use disorder and pain management providers as well as many other specialties, to obtain objective information about patients' recent use of prescription medications and/or illicit drugs and helps monitor the effectiveness of treatment plans. ARIA Diagnostics is committed to the improvement of patient care by expanding its national clinical laboratory network to provide population specific, decentralized, and clinician tailored testing.

###